Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression

Schizophrenia Clinical Trial

— GnRHa  

Official title:

Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02661789
• Other study ID #: GnRHa
• Secondary ID: H-2-2010-108
• Status: Completed
• Phase: N/A
• First received: January 13, 2016
• Last updated: January 19, 2016
• Start date: January 2011
• Est. completion date: December 2012

Study information

• Verified date: January 2016
• Source: Rigshospitalet, Denmark
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The project aimed at identifying neuropsychobiological signatures of pharmacological sex-steroid hormone manipulations in healthy women as a risk model for depression.

The study is a double-blind, randomized, placebo-controlled study. Investigators included 63 healthy female volunteers with regular menstrual cycles between 23 and 35 days. Participants were randomized to active Gonadotrophin-Releasing-Hormone agonist (GnRHa) (goserelin 3.6 mg implant) or placebo (saline injection) intervention, which was initiated in the mid follicular phase (i.e. cycle day 22.6 ±2.5). Sixty women completed follow-up and entered the analyses, except for a few drop outs on some domains. The following domains were addressed at baseline and at follow-up (16±3 days post intervention), (which corresponded to the early ovarian suppression phase of the biphasic hormone response to GnRHa): 1) serotonin transporter binding as imaged by 11CDASB Positron Emission Tomography (PET), 2) functional Magnetic Resonance Imaging (fMRI) emotional processing, 3) fMRI reward processing, 3) rating state fMRI (rsfMRI), 4) structural MRI, 5) Neuropsychology, 6) Psychophysiology, 7) Hypothalamus-Pituitary-Adrenal cortex (HPA)-axis dynamics, 8) Peripheral markers of immunoactive cell responses, 9) Epigenetic factors.

Psychometrics in terms of self reported mental distress and interview based ratings were monitored across the intervention period to monitor potential symptoms of mental distress and psychopathology. Also ovarian hormone responses, peripheral blood markers, and side effects scores were collected across the intervention period.

Description:

Aims and hypotheses:

Gender matters in normal brain function as well as in neuropsychiatric disorders. E.g. the vulnerability to mood and anxiety disorders is considerably greater in women. Among other factors, this possibly reflects gender differences in central serotonergic function since dysfunction of serotonergic neurotransmission is critically involved in the pathophysiology of mood and anxiety disorders, schizophrenia, and Alzheimer's disease. In particular, women going through phases in life where sex hormones decline rapidly from high levels or fluctuate, have a higher frequency of severe mood state changes and are more vulnerable to psychiatric disorders, e.g. across the pre to postpartum and menopausal transition. Interestingly, this risk is associated with increased variability of the plasma levels of the sex-hormone estradiol. Therefore, sex-hormone manipulation with a pharmacologically induced biphasic ovarian hormone response serve as a unique opportunity to study how sex-hormone fluctuations provoke mood state changes and increase vulnerability to neuropsychiatric disorders.

In this project investigators aimed at investigating whether sex-hormone manipulation affects: 1. Molecular imaging markers of serotonergic neurotransmission in vivo, 2. Brain structure, architecture and functional connectivity, 3. Stress and inflammatory responses, and 4. Cognitive functions, emotional processing, and information filtering, of importance in the pathophysiology of neuropsychiatric disorders.

Mentally healthy female volunteers were assessed at baseline (i.e cycle day 6.6 ±2.2) and at follow-up (i.e 16.2 ±2.6 days post intervention) in the early ovarian suppression phase af a Gonadotrophin-Releasing-Hormone agonist response in a placebo-controlled, double-blinded design (cohort size aim: N=30x2).

Research in neurobiological correlates of vulnerability related to sex-hormone changes is pivotal to improve the etiological understanding of brain disorders with gender differences in their incidence and/or nature. Such research may contribute to ameliorate fertility treatment, to improve treatment of mood disorders and schizophrenia, and, ideally, shed light on possible preventive strategies in vulnerable phases of women's lives such as the pre- to post-partum and menopausal transition period.

Hypotheses:

Investigators hypothesised that sex-hormone manipulation is associated with the following:

1. Compromised serotonergic neurotransmission, 2. Changes in functional and structural connectivity and lower hippocampal brain volumes and/or markers of decreased neurogenesis,

3. Increased stress reactivity and inflammatory responses, and 4. Changes in neurocognitive functioning and negative bias in emotional processing and information filtering. Investigators further hypothesised that these changes occur in a manner dependent on the magnitude of the estradiol drop from baseline and dependent on symptoms of depressed and anxious mood.

General study design:

The study is a prospective, double-blinded, placebo-controlled, combined within-subject and between-group design of neuropsychobiological changes in response to hormonal down-regulation. The investigation program will be performed at baseline in the mid-follicular phase, at day 5-8 of the menstrual cycle, and in the down-regulated state, 14-19 days after GnRHa intervention.

Participants. Investigators aimed at including 60 healthy female volunteers, in the age range 18-40 years. Group 1 (N=30) will receive sex-hormone manipulation with GnRHa, and group 2 (N=30) will receive placebo (saline injection). The inclusion will be stratified according to a polymorphism in the serotonin transporter promoter region (5-HTLPR).

The investigation program includes functional brain imaging of the serotonin transporter with [11C]DASB PET (6) and fMRI, structural brain imaging, blood measurements of sex-hormone levels, inflammatory and epigenetic biomarkers, characterization of the cortisol awakening response, and psychophysiological measures of information processing, and monitoring of symptoms of mental distress and psychopathology across the intervention period. An initial screening program will secure inclusion of healthy controls only and determine trait parameters such as genotypes, IQ and personality measures.

The study was registered at and approved by the Danish Ethical Committee before participant inclusion under the protocol identification number: H-2-2010-108. All participants gave written informed consent.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 63
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Healthy women

• Regular menstrual cycles (23 -35 days cycle length)

• No systemic or intrauterine steroid hormone use

Exclusion Criteria:

• Psychiatric disorder (DSM IV Axis I or WHO ICD-10 diagnostic classification).

• Prior or present neurological or other severe medical condition including substance abuse.

• No drug intake suspected to influence results

• Conditions that may increase risk by participating in the study program including ovarian cysts

• Pregnancy during the last year

• Delivery during the last 2 years

• Presently wishing to obtain pregnancy

• Breast feeding

• Not fluent in Danish or severe visual or hearing impairments

• Earlier or present learning disabilities

• Claustrophobia (due to MRI scans)

• Metal implants (excludes MRI)

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Depression
• Depression, Postpartum
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder
• Menopause
• Nerve Degeneration
• Neurodegeneration
• Postpartum Depression
• Postpartum Psychosis
• Schizophrenia

Intervention

Drug:
• Goserelin 3.6 mg implant
Pharmacologically induced biphasic sex-steroid hormone fluctuation
• Placebo
Injection of saline

Locations

Country	Name	City	State
Denmark	Neurobiology Research Unit, Rigshospitalet	Copenhagen

Sponsors (6)

Lead Sponsor	Collaborator
Gitte Moos Knudsen	Center for Integrated Molecular Brain Imaging, CNSR, Glostrup Psychiatric Center, Danish Multiple Sclerosis Center Rigshospitalet, Dept. of Clinical Immunology, Rigshospitalet, Fertility Clinic Rigshospitalet

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Ovarian hormone responses to intervention	Ovarian hormone responses to intervention, i.e. concentrations of estradiol, progesterone and testosterone in peripheral blood)	Baseline (i.e, cycle day 5-8), intervention time (i.e cycle day 21-23), flare-up phase (i.e, 3-4 days post intervention) and follow-up (i.e.,16±3 days post intervention)	No
Primary	Changes from baseline in symptoms of depression	Hamilton 17 item score	Baseline to follow-up 16±3 days after intervention	No
Primary	Changes from baseline in serotonin transporter binding in volumes of interest (VOIs)	PET scan assessed serotonin transporter binding changes	Baseline to follow-up 16±3 days after intervention	No
Primary	Changes from baseline in fMRI response to emotional faces	fMRI response changes to emotional faces in emotion processing network including amygdala reactivity	Baseline to follow-up 16±3 days after intervention	No
Primary	Changes from baseline in fMRI response to gambling paradigm	fMRI response changes to reward (monetary win) paradigm in reward processing network	Baseline to follow-up 16±3 days after intervention	No
Primary	Changes from baseline in rsfMRI changes in functional connectivity	rsfMRI changes in functional connectivity in response to intervention	Baseline to follow-up 16±3 days after intervention	No
Primary	Changes from baseline in affective cognition (VAMT-24 test)	Neuropsychological (VAMT-24 test) outcomes on affective cognition	Baseline to follow-up 16±3 days after intervention	No
Primary	Changes from baseline in reaction time	Changes in reaction time	Baseline to follow-up 16±3 days after intervention	No
Primary	Serial mood fluctuations (SD of total mood disturbance (TMD) score of daily POMS across intervention period)	Mood fluctuations measured by serial collection of daily POMS	Intervention start to follow-up 16±3 days after intervention	No
Primary	Changes from baseline in hippocampal volume	Hippocampal volumes from structural MRI	Baseline to follow-up 16±3 days after intervention	No
Primary	Changes in pre-pulse-inhibition (PPI) from baseline	Change in amplitude of the startle response to pulse after pre-pulse warning as measured by EMG in the orbicularis oculi muscle (subtraction of averages across a series of 10 repititions at baseline and at follow-up 16±3 days).	Baseline to follow-up 16±3 days after intervention	No
Primary	Changes in a set of markers of immunoactivity across study period	Cytokines, hsCRP and gene transcript profile markers of	Baseline, intervention time, flare-up phase and follow-up	No
Primary	Changes in epigenetic markers of estrogen sensitivity	Epigenetic (methylation) markers	Baseline to follow-up 16±3 days after intervention	No
Primary	Changes in HPA-axis dynamics (the cortisol awakening response)	The cortical awakening response	Baseline to follow-up 16±3 days after intervention	No
Primary	Changes in sensorimotor gating (P50 suppression) from baseline	Changes in sensorimotor gating (P50 suppression) from baseline	Baseline to follow-up 16±3 days after intervention	No
Primary	Changes from baseline in hippocampal microstructure	Hippocampal microstructure from MRI	Baseline to follow-up 16±3 days after intervention	No
Secondary	Changes from baseline in fMRI responses to emotional memory paradigm	Changes in brain activation to fMRI emotional memory paradigm - delayed recall forgetting of word prior to emotional disturbance	Baseline to follow-up 16±3 days after intervention	No
Secondary	Changes from baseline in Cohens perceived stress score	Changes Cohens perceived stress score	Baseline to follow-up 16±3 days after intervention	No
Secondary	Changes in Pittsburg Sleep Quality Inventory (PSQI)	Sleep quality self reported weekly across intervention period	Baseline and 1 time per week until follow-up at 16 ±3 days	No
Secondary	Side effects scores (project specific 15 items questionnaire)	Total side effect score across and after intervention period	7, 12 and 30 days post intervention	No
Secondary	Changes in SCL-R (Symptom check-list revised)	Changes in symptoms of psychopathology across intervention period	Baseline and 1 time per week from intervention to follow up at 16±3 days post intervention	No
Secondary	Major Depression Inventory (MDI)	Changes in self-reported symptoms of depression across intervention period	Baseline and 1 time per week from intervention to follow up at 16±3 days post intervention	No
Secondary	Changes in profile of mood states (POMS TMD score)	Changes in self-reported symptoms of mental distress across intervention period	Baseline and 1 time per week from intervention to follow up at 16±3 days post intervention	No